AstraZeneca Announced Top Line Results From Pivotal Phase III Study for BRILINT
AstraZeneca Announced Top Line Results From Pivotal Phase III Study for BRILINT
  • Healthkoreanews
  • admin@hkn24.com
  • 승인 2009.05.12 15:58
  • 댓글 0
이 기사를 공유합니다

AstraZeneca announced top line results from the phase III trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes) on 11 May.

These results demonstrate that BRILINTA(ticagrelor), the investigational oral antiplatelet treatment for acute coronary syndromes(ACS), has achieved a statistically significant primary efficacy endpoint versus clopidogrel, in the prevention of cardiovascular(CV) events in patients with ACS. The primary efficacy measure was time to first occurrence of any event from the composite of myocardial infarction, stroke, and CV death.

In PLATO, the overall safety profile for BRILINTA was in line with the safety data observed in the phase II studies. Given the size of the PLATO trial, further analysis of the entire database, secondary variables, and subgroups is ongoing. AstraZeneca and the PLATO Executive Committee’s aim is to submit the PLATO data to a peer-reviewed medical journal and present at the European Society of Cardiology (ESC) annual meeting in August 2009.

PLATO was a head-to-head outcomes study of BRILINTA versus clopidogrel to establish whether BRILINTA could achieve meaningful cardiovascular and safety endpoints in ACS patients.

It is estimated that one in three ACS patients will die, have a recurrent heart attack(also known as myocardial infarction), or be readmitted to hospital within six months of their first cardiovascular event so preventing reoccurrence is vital in ACS patient treatment.

The study involved 18,624 ACS patients in 43 countries and was designed to provide a comprehensive analysis of efficacy, safety and tolerability of BRILINTA. The PLATO study was led by the Executive Committee co-chairs, Professor Lars Wallentin, Sweden (Uppsala Clinical Research Center) and Professor Robert Harrington, USA (Duke Clinical Research Institute).

The submission of BRILINTA to regulatory authorities remains on schedule for the fourth quarter of 2009.<헬스코리아뉴스>

댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

      • 회사명 : (주)헬코미디어
      • 서울특별시 마포구 매봉산로2길 45, 302호(상암동, 해나리빌딩)
      • 대표전화 : 02-364-2002
      • 청소년보호책임자 : 이슬기
      • 제호 : 헬스코리아뉴스
      • 발행일 : 2007-01-01
      • 등록번호 : 서울 아 00717
      • 재등록일 : 2008-11-27
      • 발행인 : 임도이
      • 편집인 : 이순호
      • 헬스코리아뉴스에서 발행하는 모든 저작물(컨텐츠, 기사)는 저작권법의 보호를 받는 바, 무단·전재·복제·배포 등을 금합니다.
      • 「열린보도원칙」 당 매체는 독자와 취재원 등 뉴스이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고
        있음을 알려드립니다. 고충처리인 이슬기 02-364-2002 webmaster@hkn24.com
      • Copyright © 2024 헬스코리아뉴스. All rights reserved. mail to admin@hkn24.com
      ND소프트
      편집자 추천 뉴스
      베스트 클릭